Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY24 results · Oct–Dec 2023
Aarti Drugs reported revenue from operations of ₹605.94 crore (down 8.7% from Q3 FY23) and net profit of ₹36.71 crore (up 0.1% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 605.94 | 663.96 | −8.7% | 641.54 | −5.5% |
| Other income | 1.67 | 1.01 | +65.3% | 0.68 | +145.6% |
| Total income | 607.61 | 664.97 | −8.6% | 642.22 | −5.4% |
| Profit before tax | 51.55 | 49.68 | +3.8% | 56.27 | −8.4% |
| Net profit for the period | 36.71 | 36.67 | +0.1% | 39.60 | −7.3% |
| Attributable to shareholders of the company | 36.67 | 36.68 | −0.0% | 39.59 | −7.4% |
| EPS, basic (₹) | 3.99 | 3.96 | +0.8% | 4.29 | −7.0% |
| Net margin (%) | 6.1 | 5.5 | 6.2 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 538.21 | 625.53 | −14.0% | 577.54 | −6.8% |
| Other income | 1.68 | 0.97 | +73.2% | 0.74 | +127.0% |
| Total income | 539.89 | 626.50 | −13.8% | 578.28 | −6.6% |
| Profit before tax | 42.87 | 48.96 | −12.4% | 46.83 | −8.5% |
| Net profit for the period | 31.62 | 36.71 | −13.9% | 34.58 | −8.6% |
| EPS, basic (₹) | 3.44 | 3.96 | −13.1% | 3.75 | −8.3% |
| Net margin (%) | 5.9 | 5.9 | 6.0 |
Consolidated
- Filed with BSE
- 25 Jan 2024, 11:53 IST
- Board meeting
- 24 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Jan 2024, 11:53 IST
- Board meeting
- 24 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Audited
- Source
- XBRL filing on BSE